Login to Your Account

Other News To Note

Thursday, August 11, 2011
Salix Pharmaceuticals Ltd., of Raleigh, N.C., said in its second quarter earnings update that it will continue to develop Xifaxan (rifaximin) 550-mg tablets for irritable bowel syndrome (IBS).

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription